{"result": {"id": "1aff8f49-758c-44e8-bc27-4adaa9e87eed", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>横纹肌溶解症<|>EVENT<|>Rhabdomyolysis, a rare but serious potential side effect of statin drugs\")\n##\n(\"entity\"<|>肌炎<|>EVENT<|>Myositis, a muscle inflammation condition that can be caused by statin drugs\")\n##\n(\"entity\"<|>肝功能异常<|>EVENT<|>Abnormal liver function, a potential side effect of statin medications\")\n##\n(\"entity\"<|>他汀类药物相关肌痛<|>EVENT<|>Statin-associated muscle pain, a common adverse effect of these medications\")\n##\n(\"entity\"<|>新发糖尿病<|>EVENT<|>New-onset diabetes, a potential long-term risk associated with high-dose statin use\")\n##\n(\"entity\"<|>胆固醇吸收抑制剂<|>ORGANIZATION<|>Cholesterol absorption inhibitors, a class of drugs used in combination with statins\")\n##\n(\"entity\"<|>脂必泰<|>ORGANIZATION<|>Zhibitai, a Chinese herbal compound containing red yeast rice for cholesterol reduction\")\n##\n(\"entity\"<|>贝特类药物<|>ORGANIZATION<|>Fibrates, a class of drugs primarily used for triglyceride reduction\")\n##\n(\"entity\"<|>ω-3脂肪酸<|>ORGANIZATION<|>Omega-3 fatty acids, used as triglyceride-lowering agents\")\n##\n(\"relationship\"<|>横纹肌溶解症<|>他汀类药物相关肌痛<|>Rhabdomyolysis represents the most severe form of statin-associated muscle symptoms<|>7)\n##\n(\"relationship\"<|>肌炎<|>他汀类药物相关肌痛<|>Myositis is an inflammatory form of statin-associated muscle symptoms<|>6)\n##\n(\"relationship\"<|>胆固醇吸收抑制剂<|>LDL-C<|>Cholesterol absorption inhibitors help further reduce LDL-C when combined with statins<|>7)\n##\n(\"relationship\"<|>脂必泰<|>LDL-C<|>Zhibitai has cholesterol-lowering effects similar to moderate-intensity statins<|>6)\n##\n(\"relationship\"<|>贝特类药物<|>TG<|>Fibrates are primarily used to reduce triglyceride levels<|>8)\n##\n(\"relationship\"<|>ω-3脂肪酸<|>TG<|>Omega-3 fatty acids are effective at lowering triglyceride levels<|>7)\n##\n(\"relationship\"<|>新发糖尿病<|>ASCVD<|>While statins may increase diabetes risk, their benefits for ASCVD prevention outweigh this risk<|>5)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752165907, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 585, "prompt_tokens": 3391, "total_tokens": 3976, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3328}, "prompt_cache_hit_tokens": 3328, "prompt_cache_miss_tokens": 63}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 类药物适用于高胆固醇血症、混合型高脂血 症和 ASCVD 的防治。他汀类药物还可使 TG 水平降低 7%~30%，HDL-C 水平升高 5%~15%。不同种类与剂量 的他汀类药物降胆固醇幅度有一定差别，但任何一种他 汀类药物剂量增倍时，LDL-C 水平进一步降低幅度仅 约为 6%。他汀类药物可在任何时间段每天服用 1 次， 但晚上服用时 LDL-C 降幅会稍增加。\n　　中等强度他汀类药物指 LDL-C 降幅 25%~50% 时所 采用的他汀类药物日剂量。不同种类与剂量的他汀类药 物降低 LDL-C 的幅度见表 3。\n表 3    他汀类药物降胆固醇强度\nTable 3    The cholesterol reduction intensity of stains\n降胆固醇强度\t药物及其剂量\n高强度\n（每日剂量可降低 LDL-C ≥ 50%）\t　阿托伐他汀 40~80 mg 瑞舒伐他汀 20 mg\n\n\n\n中等强度\n（每日剂量可降低 LDL-C 25%~<50%）\t阿托伐他汀 10~20 mg\n瑞舒伐他汀 5~10 mg 氟伐他汀 80 mg\n洛伐他汀 40 mg\n匹伐他汀 1~4 mg\n普伐他汀 40 mg\n辛伐他汀 20~40 mg 血脂康 1.2 g\n　　如应用中等强度他汀类药物（避免使用大剂量他汀 类药物）后 LDL-C 仍不达标，则考虑联合治疗（联合 胆固醇吸收抑制剂或 / 和 PCSK9 抑制剂或其他药物）。 在应用他汀类药物期间，需关注与其他药物间的相互作 用。通过 CYP3A4 途径代谢的他汀类药物与免疫抑制剂 （如环孢菌素 A 等）、抗真菌药物、大环内酯类药物、 胺碘酮、吉非罗齐以及西柚汁等联用时，可能增加肌病 或肌溶解的风险，故使用上述药（食）物的患者应避免 使用大剂量他汀类药物并监测不良反应。\n应用他汀类药物使 LDL-C 达标后应继续长期应用，\n\n\n\n 中国全科医学      2024年7月 第27卷 第20期\n如能耐受应避免停用。\n　　　目前报道的他汀类药物不良反应主要包括肝功能异 常、他汀类药物相关肌痛、肌酶升高、肌炎、横纹肌溶 解症（图 4） ，多呈剂量依赖性。长期、大剂量服用他 汀类药物有增加新发糖尿病的风险，但其对 ASCVD 的 总体益处远大于新发糖尿病的风险。\n\n\nhttps://www.chinagp.net    E-mail: zgqkyx@chinagp.net.cn     ·2433 ·\n用剂量为 0.5 g，2 次 /d。\n4.1.5   其他降脂药脂必泰是一种红曲与中药（山楂、泽 泻、白术）的复合制剂，具有降低胆固醇的作用。\n4.2    主要降 TG 药物\n　　主要降 TG 的药物包括贝特类药物、ω-3 脂肪酸、 �\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>ASCVD<|>EVENT<|>ASCVD refers to atherosclerotic cardiovascular disease, a condition targeted by statin drugs for prevention and treatment\")\n##\n(\"entity\"<|>LDL-C<|>EVENT<|>Low-density lipoprotein cholesterol, a primary target for reduction by statin drugs\")\n##\n(\"entity\"<|>HDL-C<|>EVENT<|>High-density lipoprotein cholesterol, which can be increased by statin drugs\")\n##\n(\"entity\"<|>TG<|>EVENT<|>Triglycerides, which can be reduced by statin drugs\")\n##\n(\"entity\"<|>阿托伐他汀<|>ORGANIZATION<|>Atorvastatin, a high-intensity statin drug available in 10-80 mg doses\")\n##\n(\"entity\"<|>瑞舒伐他汀<|>ORGANIZATION<|>Rosuvastatin, a high-intensity statin drug available in 5-20 mg doses\")\n##\n(\"entity\"<|>氟伐他汀<|>ORGANIZATION<|>Fluvastatin, a medium-intensity statin drug\")\n##\n(\"entity\"<|>洛伐他汀<|>ORGANIZATION<|>Lovastatin, a medium-intensity statin drug\")\n##\n(\"entity\"<|>匹伐他汀<|>ORGANIZATION<|>Pitavastatin, a medium-intensity statin drug\")\n##\n(\"entity\"<|>普伐他汀<|>ORGANIZATION<|>Pravastatin, a medium-intensity statin drug\")\n##\n(\"entity\"<|>辛伐他汀<|>ORGANIZATION<|>Simvastatin, a medium-intensity statin drug\")\n##\n(\"entity\"<|>血脂康<|>ORGANIZATION<|>Xuezhikang, a Chinese red yeast rice preparation with cholesterol-lowering effects\")\n##\n(\"entity\"<|>PCSK9抑制剂<|>ORGANIZATION<|>PCSK9 inhibitors, a class of cholesterol-lowering drugs used in combination therapy\")\n##\n(\"entity\"<|>CYP3A4<|>ORGANIZATION<|>Cytochrome P450 3A4 enzyme involved in statin metabolism\")\n##\n(\"entity\"<|>中国全科医学<|>ORGANIZATION<|>Chinese General Practice, the medical journal publishing this information\")\n##\n(\"relationship\"<|>阿托伐他汀<|>LDL-C<|>Atorvastatin reduces LDL-C levels by 25-50% at medium doses and >50% at high doses<|>8)\n##\n(\"relationship\"<|>瑞舒伐他汀<|>LDL-C<|>Rosuvastatin reduces LDL-C levels by 25-50% at medium doses and >50% at high doses<|>8)\n##\n(\"relationship\"<|>血脂康<|>LDL-C<|>Xuezhikang reduces LDL-C levels by 25-50%<|>7)\n##\n(\"relationship\"<|>PCSK9抑制剂<|>LDL-C<|>PCSK9 inhibitors are used when statins alone cannot achieve LDL-C targets<|>6)\n##\n(\"relationship\"<|>CYP3A4<|>阿托伐他汀<|>Atorvastatin is metabolized through the CYP3A4 pathway<|>7)\n##\n(\"relationship\"<|>CYP3A4<|>辛伐他汀<|>Simvastatin is metabolized through the CYP3A4 pathway<|>7)\n##\n(\"relationship\"<|>ASCVD<|>LDL-C<|>Reducing LDL-C is a primary strategy for ASCVD prevention<|>9)\n##\n(\"relationship\"<|>中国全科医学<|>ASCVD<|>Chinese General Practice published these ASCVD treatment guidelines<|>5)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_72ffeafa99a04c20982d3f2741f804a9b514e6d80497b2280bc881b859f22f5c_v2"}